Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting
June 04, 2024 08:00 ET
|
Cyclacel
- Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific mechanism of action - BERKELEY HEIGHTS, N.J., June 04, 2024 (GLOBE NEWSWIRE) --...
Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for Cancer
June 03, 2024 08:00 ET
|
Cyclacel
CYCLACEL PHARMACEUTICALS REPORTS NEW CLINICAL DATA AT 2024 ASCO ANNUAL MEETING HIGHLIGHTING ORAL FADRACICLIB’S POTENTIAL AS A PRECISION MEDICINE FOR CANCER
Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
May 14, 2024 16:05 ET
|
Cyclacel
- New Clinical Data to be Presented at ASCO Annual Meeting Highlighting Potential Precision Medicine Strategy with Oral Fadraciclib -- First Patients Enrolled in Oral Fadraciclib Phase 2 Proof of...
Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results
May 08, 2024 09:15 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules
May 02, 2024 16:30 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
April 30, 2024 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
April 01, 2024 09:15 ET
|
Cyclacel
- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid tumors and lymphoma - BERKELEY HEIGHTS, N.J.,...
Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
March 07, 2024 09:15 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., March 07, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
March 06, 2024 09:15 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...
Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference
February 20, 2024 09:15 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...